No Carolina / New York / Florida        Ph: 561.316.3330

MolecuLight Reports 10 Clinical Posters and Video Presentations at SAWC

What To Know

  • “The key clinical outcomes – from improved wound assessment and treatment planning, point-of-care monitoring of wound cleaning and debridement efficacy, and the ability to detect biofilm in wounds – all illustrate the significant clinical improvements to wound care provided to clinicians by the MolecuLight i.
  • “We are thrilled to have had a record number of MolecuLight-based clinical posters and presentations, from so many wound care professionals and settings, be included at the SAWC’s Virtual Session”, says Anil Amlani, MolecuLight’s CEO.

MolecuLight reports 10 Clinical Posters and Video Presentations took place at SAWC Spring 2020, held virtually from July 24 – 26, 2020. SAWC is one of the largest multidisciplinary meetings of wound care professionals.

“We are thrilled to have had a record number of MolecuLight-based clinical posters and presentations, from so many wound care professionals and settings, be included at the SAWC’s Virtual Session”, says Anil Amlani, MolecuLight’s CEO. “The key clinical outcomes – from improved wound assessment and treatment planning, point-of-care monitoring of wound cleaning and debridement efficacy, and the ability to detect biofilm in wounds – all illustrate the significant clinical improvements to wound care provided to clinicians by the MolecuLight i:X. Evidence for cost savings stemming from earlier detection of high bacterial loads, also presented at this meeting, demonstrates the significant health economic benefit that goes along with these improvements to patient care.”

A submission on MolecuLight by Rosemary Hill, CWOCN and Kevin Woo, RN PhD was one of the top 4 scoring abstracts, out of more than 200 submissions. This is the fourth consecutive SAWC meeting where an abstract on patient care improvements achieved through MolecuLight’s bacterial-detection technology has received this honour.

The 10 clinical posters and newly-available video abstracts featuring the MolecuLight i:X from SAWC Virtual are as follows:

  • Poster PI-002 – Highest Scoring for Oral/Podium Presentation
    Using the UPPER/LOWER Infection Checklists and Real-time Fluorescence Imaging: A Complimentary Approach to Wound Assessment
    Rosemary Hill 
    Watch the Clinical Presentation

  • Poster GR-05:
    Real-world Evidence Demonstrating Utility of Bacterial Fluorescence Imaging to Guide Treatment Decision Making in 283 Wounds
    Laura M. Jones, Ashley Jacob, Alyssa Mackey, Nathan Krehbiel, Anna D’souza, Monique Y. Rennie
    Watch the Video Abstract

  • Poster EBP-009:
    Superabsorbent Dressing Impact on Fluorescing Bacteria in the Real-World Setting
    Catherine Milne
    Download Poster

  • Poster EBP-008:
    Evaluation of a Novel Antimicrobial Topical Spray to Reduce Bioburden
    Catherine Milne
    Download Poster

  • Poster CR-026:
    Stopping the Guesswork: Using Point-of-care Fluorescence Imaging to Guide Antibiotic Stewardship
    Monique Rennie
    Download Poster

  • Poster CR-027:
    Fluorescence Imaging and Delayed Healing Are the Only Significant Predictors of Bacterial Loads >10,000 CFU/g: Data from 350 Wounds
    Monique Y. Rennie, Liis Teene, Anna D’souza, Thomas Serena
    Watch the Video Abstract

  • Poster GR-12:
    Quantitative vs. Semi-quantitative Measurements of Bacterial Load in Wounds: Assessment of 1053 Data Points from 41 Bacterial Species in a 350-patient Trial
    Monique Y. Rennie, Liis Teene, Anna D’souza, Thomas Serena
    Watch the Video Abstract

  • Poster GR-20:
    An Evidence-based Decision Tree Using Fluorescence Imaging to Address Bacterial Load Per International Guidelines
    Liis Teene, Anna D’souza, Monique Y. Rennie
    Watch the Video Abstract

  • Poster HE-012:
    Health Economics of Fluorescence Imaging: Realized Cost Savings with Appropriate Treatment of Bacteria in Chronic Wounds
    Monique Y. Rennie, Liis Teene
    Download Poster

  • Poster M LR-044:
    In vivo Detection of Bacteria Within a Biofilm Using a Point-of-care Fluorescence Imaging Device
    Andrea J. Lopez, Landrye Reynolds, Rachel Diaz, Isiah George, William Little, Laura M. Jones PhD, Monique Y. Rennie PhD, Allie Clinton Smith, PhD
    Watch the Video Abstract

In the Virtual SAWC exhibit hall, MolecuLight also shared its new US reimbursement pathway (as of July 1, 2020) that includes two CPT® codes (Category III) for physician work and facility payment for Hospital Outpatient Department (HOPD) and Ambulatory Surgical Center (ASC) settings through an Ambulatory Payment Classification (APC) assignment. These new codes were issued by the AMA and CMS, respectively, after a critical review of the large body of supporting clinical evidence, and with each body recognizing the medical necessity of this procedure.

Latest

Unlocking New Hope: Alzheimer’s Patients Join Amyloid-Targeting Therapy Study

The study is designed to assess the clinical utility and workflow benefits of Swoop® system images acquired at infusion centers and clinics to help physicians detect amyloid-related imaging abnormalities (ARIA) in Alzheimer’s patients receiving amyloid-targeting therapy at the times specified in the labeling (before the fifth, seventh, and fourteenth infusions).

Indaptus Therapeutics Presents Positive Mechanism of Action Data at the American Association for Cancer Research Annual Meeting

Dr. Michael Newman, Indaptus’ Founder, Chief Scientific Officer, and lead author, commented, “The new data are consistent with our preclinical animal tumor model studies and provide evidence for our hypothesis that patented Decoy bacteria can activate a wide range of innate and adaptive human immune cells involved in fighting tumors.  This aligns with what we’ve observed in our ongoing Phase 1 clinical trial of Decoy20 – broad immune activation, as evidenced by transiently increased levels of many key cytokines and chemokines following single dose administration. These findings bolster our confidence in Decoy20's potential as a multifaceted immunotherapy.”

Enliven Therapeutics Announces Positive Proof of Concept Data from Phase 1 Clinical Trial of ELVN-001 in Chronic Myeloid Leukemia

“We are excited to present the first look at the safety and clinical activity of ELVN-001, which we believe supports the potential for ELVN-001 to address the limitations of the available active-site TKIs,” said Helen Collins, M.D., Chief Medical Officer of Enliven. “Across a wide dose range, ELVN-001 demonstrated activity in a heavily pre-treated patient population that includes post-asciminib patients, with a preliminary safety profile consistent with its highly selective design. Not only did all evaluable patients have improved or stable BCR::ABL1 transcript levels, but, importantly, 89% of all patients enrolled remain on study. We believe the initial data demonstrate the potential clinical utility of ELVN-001 for all types of patients, including those that are earlier in the treatment paradigm.”

Ferring Presents Pivotal Phase 3 Efficacy and Safety Data for Investigational Treatment, SI-6603 (condoliase), in Lumbar Disc Herniation at ASIPP 2024

The research, presented at the American Society of Interventional Pain Physicians (ASIPP) Annual Meeting, included a registrational Phase 3 trial and an integrated safety analysis of six clinical studies, as well as a real-world analysis of current treatment options and gaps in the clinical management of patients with newly-diagnosed LDH.

By using this website you agree to accept Medical Device News Magazine Privacy Policy